10-K: CEL-SCI Corporation Reports Fiscal Year 2024 Results, Focuses on Multikine Confirmatory Study

CEL-SCI Corporation announces its fiscal year 2024 results, highlighting progress towards a confirmatory study for Multikine in head and neck cancer treatment.

Summary

• CEL-SCI Corporation, a late clinical-stage biotechnology company, reported its fiscal year 2024 results, with a focus on its lead investigational therapy, Multikine, for head and neck cancer.
• The company incurred a net operating loss of approximately $26.4 million for the twelve months ended September 30, 2024.
• Research and development expenses decreased by approximately $4.3 million, or 19%, compared to the year ended September 30, 2023.
• General and administrative expenses decreased by approximately $0.8 million, or 9%, compared to the year ended September 30, 2023.
• As of September 30, 2024, CEL-SCI had cash and cash equivalents of approximately $4.7 million.
• The company is planning to initiate a 212-patient confirmatory registration study for Multikine in Q1 2025, with full enrollment expected in Q2 2026.
• CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements.
• The company is seeking regulatory approval for Multikine following full enrollment of its confirmatory study.
• CEL-SCI is also developing LEAPS technology for potential treatment of rheumatoid arthritis, but its primary focus is on Multikine.
• The company has identified material weaknesses in its internal control over financial reporting as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and regulatory pathways, the financial losses and going concern uncertainty weigh negatively.

Positives

• FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.
• The company observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]) in the Phase III study.
• The confirmatory study is expected to initiate in Q1 2025 and reach full enrollment in Q2 2026.
• Research and development expenses decreased by approximately $4.3 million, or 19%, compared to the year ended September 30, 2023.
• General and administrative expenses decreased by approximately $0.8 million, or 9%, compared to the year ended September 30, 2023.

Negatives

• CEL-SCI incurred a net operating loss of approximately $26.4 million for the twelve months ended September 30, 2024.
• As of September 30, 2024, CEL-SCI had cash and cash equivalents of approximately $4.7 million.
• CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements.
• The company has identified material weaknesses in its internal control over financial reporting as of September 30, 2024.

Risks

• CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
• CEL-SCI will require substantial additional capital to remain in operation.
• A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates development or commercialization efforts.
• The costs of the product candidates development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.
• CEL-SCI depends heavily on the success of Multikine, for which Phase III results have been announced, while its other candidates are still in preclinical phases.
• CEL-SCIs product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products.
• Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.
• CEL-SCIs product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.
• Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCIs operations.
• The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.
• CEL-SCIs commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.
• CEL-SCIs patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.
• Much of CEL-SCIs intellectual property is protected as trade secrets or confidential know-how, not by patents.
• You may experience future dilution as a result of future equity offerings or other equity issuances by CEL-SCI.
• The price of CEL-SCIs common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCIs shareholders.

Future Outlook

CEL-SCI is aiming to begin enrollment for a 212-patient confirmatory registration study in Q1 2025, with full enrollment expected in Q2 2026 with the potential to seek early approval after full enrollment.

Industry Context

The document mentions that the global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc.

Comparison to Industry Standards

• The document mentions Keytruda and Opdivo, checkpoint inhibitors, which appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction.
• The document states that Multikine works best in tumors with low PD-L1 expression, whereas available checkpoint inhibitors work best on tumors with high PD-L1 expression.

Related Party Transactions

• During the year ended September 30, 2024, officers and a director of the Company purchased 58,000 restricted shares of the Companys common stock at an aggregate market value of approximately $80,620.
• On July 11, 2024, Geert Kersten, the Companys Chief Executive Officer and a director, loaned the Company $200,000.
• On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000.
• On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Companys CEO, Geert Kersten, is a beneficiary.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.
• The success of Multikine is critical for the company's future and will impact patients, physicians, and the medical community.

Next Steps

• Initiate the confirmatory study in Q1 2025.
• Reach full enrollment in Q2 2026.
• Seek regulatory approval of Multikine following full enrollment of the confirmatory study.

Key Dates

Keywords

Multikine, CEL-SCI, Head and Neck Cancer, Immunotherapy, Clinical Trial, LEAPS, Regulatory Approval, Financial Results, Biotechnology, Oncology